← Back to patent-cliff list
Merigolix
Tier C — Watch / tradeMerigolix
TiumBio Co Ltd
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：GnRHR
Indications (approved)：女性不孕, 子宫肿瘤, Endometriosis, Menorrhagia
Regional status
US
-
EU
Phase II
2021-08-19
China
Phase II
2026-01-23
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Merigolix?
Approved indications include: 女性不孕, 子宫肿瘤, Endometriosis, Menorrhagia.
When does the Merigolix patent expire?
No public expiry year is available for Merigolix yet; this page updates once verified.
How do I get a quote for Merigolix intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06